Last reviewed · How we verify
rilzabrutinib SAR444671
At a glance
| Generic name | rilzabrutinib SAR444671 |
|---|---|
| Sponsor | Principia Biopharma, a Sanofi Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease (PHASE3)
- A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease (PHASE2)
- The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease (PHASE3)
- A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia (PHASE3)
- Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment (PHASE3)
- Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan (PHASE3)
- Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants (PHASE2)
- Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rilzabrutinib SAR444671 CI brief — competitive landscape report
- rilzabrutinib SAR444671 updates RSS · CI watch RSS
- Principia Biopharma, a Sanofi Company portfolio CI